Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. III. Radiation treated patients
Serum prostate specific antigen was determined (Yang polyclonal radioimmunoassay) in 183 men after radiation therapy for adenocarcinoma of the prostate. A total of 163 men had received 7,000 rad external beam radiotherapy and 20 had been implanted with iodine-125 seeds. Only 11 per cent of these 183 patients had undetectable prostate specific antigen levels at a mean interval of 5 years since completion of radiotherapy. Prostate specific antigen levels after radiotherapy were directly related to initial clinical stage and Gleason score before treatment. Multiple prostate specific antigen determinations were performed with time in 124 of 183 patients. During year 1 after radiotherapy prostate specific antigen levels were decreasing in 82 per cent of the patients but only 8 per cent continued to decrease beyond year 1. Of 80 patients observed greater than 1 year after completion of radiotherapy 51 per cent had increasing values and 41 per cent had stable values. Increasing prostate specific antigen values after radiotherapy were correlated with progression to metastastic disease and residual cancer on prostate biopsy. Total serum acid phosphatase levels were poorly related to prostate specific antigen levels, were less effective in discriminating patients with metastatic disease and provided no additional information beyond that provided by prostate specific antigen.
- Research Organization:
- Stanford Univ. Medical Center, CA (USA)
- OSTI ID:
- 6071213
- Journal Information:
- J. Urol.; (United States), Vol. 141:5
- Country of Publication:
- United States
- Language:
- English
Similar Records
Results of a phase II trial of transrectal ultrasound-guided permanent radioactive implantation of the prostate for definitive management of localized adenocarcinoma of the prostate (Radiation Therapy Oncology Group 98-05)
Radiation Dose Predicts for Biochemical Control in Intermediate-Risk Prostate Cancer Patients Treated With Low-Dose-Rate Brachytherapy
Related Subjects
ANTIGENS
SPECIFICITY
CARCINOMAS
DIAGNOSIS
RADIOTHERAPY
PROSTATE
ACID PHOSPHATASE
BIOLOGICAL MARKERS
IODINE 125
PATIENTS
RADIATION SOURCE IMPLANTS
RADIOIMMUNOASSAY
BETA DECAY RADIOISOTOPES
BODY
DAYS LIVING RADIOISOTOPES
DISEASES
ELECTRON CAPTURE RADIOISOTOPES
ENZYMES
ESTERASES
GLANDS
HYDROLASES
IMMUNOASSAY
IMMUNOLOGY
IMPLANTS
INTERMEDIATE MASS NUCLEI
IODINE ISOTOPES
ISOTOPE APPLICATIONS
ISOTOPES
MALE GENITALS
MEDICINE
NEOPLASMS
NUCLEAR MEDICINE
NUCLEI
ODD-EVEN NUCLEI
ORGANS
PHOSPHATASES
RADIATION SOURCES
RADIOASSAY
RADIOIMMUNOLOGY
RADIOISOTOPES
RADIOLOGY
THERAPY
TRACER TECHNIQUES
550603* - Medicine- External Radiation in Therapy- (1980-)
550601 - Medicine- Unsealed Radionuclides in Diagnostics